5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Mankind Pharma Ltd.

•
mankindpharma.comBSE: 543904NSE: MANKIND
Market Cap₹ 93,596 Cr.
Current Price
High / Low₹ 2,674 / 1,910
Stock P/E42.9
Book Value₹ 409
Price to Book5.06
Dividend Yield0.04 %
ROCE13.3 %
ROE13.3 %
Face Value₹ 1

Add ratio to table

ABOUT

KEY POINTS

Revenue Breakup Mar 2019 • Pharmaceutical and other related products: 100.0%

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Latest quarter profit grew 35.3% YoY, showing strong momentum
  • Operating margins have improved to 28.7% from 22.0%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 1.24x)
  • Working capital cycle has improved - days down from -9 to -44
  • Company generates healthy free cash flow
  • Stock looks reasonably valued - P/E of 42.9 is below its historical median

CONS

  • Receivables are growing faster than sales - a possible quality concern
  • Promoter holding has decreased over last 2 years: -2.2pp
  • Stock is trading at 5.1x its book value
  • Though reporting repeated profits, the company pays out little dividend (2.0%)
  • Expensive relative to growth - PEG of 2.4

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTY PHARMANIFTYLARGEMIDCAP250NIFTYMIDCAP150NIFTY MIDCAP 100NIFTY MIDCAP 150
S.No.Name
1.SUNPHARMA1868.5037.06448315.740.862901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9482.7586.06251737.220.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4931.9086.01187593.620.77566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1129.0024.95112618.180.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1368.0032.79110515.040.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1933.2595.54104455.860.10362.07123.942026.3129.1018.2031.50
7.AUROPHARMA1690.0026.1997238.860.241032.0325.229150.3517.4412.7620.54
8.LUPIN2092.0017.3095660.020.861416.9816.018276.8934.2828.8629.59
9.DRREDDY1143.2029.6195420.610.70435.60-69.108099.80-5.2113.7510.63
10.MANKIND2266.0045.8293596.020.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2439.5538.2968850.120.10482.83927.884018.4831.3520.3520.03
12.BIOCON395.00129.9764372.920.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
2,0922,2602,2092,0072,4132,5442,4312,1192,5412,6092,6332,5822,964
1,5941,6621,6361,4821,8371,7811,6881,7781,8681,9161,8541,6632,241
Operating Profit498598573526576763743342673693778919723
OPM %23.80%26.46%25.94%26.19%23.88%30.01%30.58%16.13%26.48%26.57%29.56%35.59%24.38%
5758678596107702206478-2710434
Interest24447320316514714713812595
Depreciation697790879190981159799108109111
Profit before Tax485575546520574778513281494525505788757
Tax %21.68%22.29%15.32%14.50%17.02%21.17%20.95%16.45%16.39%12.53%11.05%9.44%26.18%
Net Profit380447463444476613405235413459449714558
10.2211.1511.5511.0911.8915.3110.085.7010.0011.1210.8917.2913.53

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
3,4953,9183,8294,7945,5237,4868,1278,6299,50710,42110,787
2,7933,1393,1243,5504,1515,6486,4296,3627,0827,3357,674
Operating Profit7017797051,2441,3721,8381,6982,2672,4253,0863,113
OPM %20.07%19.87%18.41%25.95%24.84%24.56%20.89%26.27%25.51%29.61%28.86%
892016494155204163270493220189
Interest21940118482817378562506
Depreciation1628386278123270335395429427
Profit before Tax7729336911,2651,4401,8711,5632,1852,1462,3152,574
Tax %31.13%26.44%25.64%24.25%24.71%25.76%20.13%18.88%19.65%11.98%15.31%
Net Profit5326865149581,0841,3891,2481,7731,7252,0382,180
EPS13.4417.3312.8323.9227.0734.6831.1644.2541.8049.36—
Dividend Payout %0.00%25.40%34.68%12.96%0.00%0.00%0.00%0.00%0.00%2.03%—

COMPOUNDED SALES GROWTH

10 Years:
13%
5 Years:
14%
3 Years:
9%

COMPOUNDED PROFIT GROWTH

10 Years:
16%
5 Years:
13%
3 Years:
18%

STOCK PRICE CAGR

10 Years:
—
5 Years:
—
3 Years:
8%
1 Year:
-14%

RETURN ON EQUITY

10 Years:
21%
5 Years:
18%
3 Years:
16%
Last Year:
13%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2025

Aug 8

₹ 1

Rs.1.0000 per share(100%)Interim Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital20404040404040404141
2,6192,9573,0253,6114,6946,5007,7449,63914,23816,308
103782001714571223327,2055,379
Trade Payables368452387487594921802525570681
1551821993543947657621,2802,4042,043
Total Liabilities3,1724,0093,8514,5105,8678,9399,37111,51624,45824,452
4815237689399822,9213,1373,5464,0763,926
Capital Work in Progress141322210144166355438135191387
9861,4021,6981,7842,3972,5263,1024,21516,68316,523
5224694825338271,2671,0321,1261,0981,088
00000007699091,164
Cash & Bank928172198477139155484306159
9491,2126219121,0191,7311,5071,2411,1951,205
Total Assets3,1724,0093,8514,5105,8678,9399,37111,51624,45824,452

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
7357907821,2341,3811,2822,0841,7362,3502,752
Cash from Investing-513-516-306-396-1,127-1,360-1,041-1,665-12,114-388
Cash from Financing-18-240-55989579-710-59,816-2,477
-831-95-5540486652-113

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
74.8774.8772.7172.7072.6872.6772.6672.6672.63
11.5812.3713.3412.9213.0712.8311.3410.249.45
9.949.9111.0511.4411.4611.8713.2214.4215.35
Government0.000.000.000.000.000.000.000.000.00
3.612.862.902.932.792.612.792.682.57

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-07
General Updates

2026-09-07 - Update on Voluntary Liquidation of Bharat Serums and Vaccines Limited, a WOS.

2026-09-01
ESOP/ESOS/ESPS

2026-09-01 - Mankind Pharma Limited has informed the Exchange regarding Allotment of 49112 Shares.

2026-08-31
General Updates

2026-08-31 - Mankind Pharma Limited has informed the Exchange about General Updates

2026-08-30
Cessation

2026-08-30 - Mankind Pharma Limited has informed the Exchange regarding Cessation of Mr Bharat Anand as Non- Executive Independent Director of the company w.e.f. August 30, 2026.

2026-08-26
Other Restructuring

2026-08-26 - Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly owned material subsidiary, into the Company by way of voluntary liquidation.

2026-08-26
Outcome of Board Meeting

2026-08-26 - Please find attached outcome of Board Meeting held today, according consent of the Board of Directors of the Company for the integration of Bharat Serums and Vaccines Limtied, a wholly owned material subsidiary, into the Company by way of voluntary liquidation.

2026-08-22
General Updates

2026-08-22 - Mankind Pharma Limited has informed the Exchange about General Updates

2026-08-20
Press Release

2026-08-20 - Mankind Pharma Limited has informed the Exchange regarding a press release dated August 20, 2026, titled "Mankind Pharma Enters into Exclusive In-Licensing Agreement for Insulin Degludec and Insulin Degludec + Aspart Combination for India".

2026-08-19
Copy of Newspaper Publication

2026-08-19 - Mankind Pharma Limited has informed the Exchange about Copy of Newspaper Publication

News

Recent coverage and analyst commentary for MANKIND

Loading news…

🤖

AI Stock Analyst

Mankind Pharma Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login